Wu X, Vallance B A, Boyer L, Bergstrom K S B, Walker J, Madsen K, O'Kusky J R, Buchan A M, Jacobson K
Div. of Gastroenterology, BC Children's Hospital, 4480 Oak St., Rm. K4-181, Vancouver, BC, Canada V6H 3V4.
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G295-306. doi: 10.1152/ajpgi.00173.2007. Epub 2007 Nov 21.
Saccharomyces boulardii has received increasing attention as a probiotic effective in the prevention and treatment of infectious and inflammatory bowel diseases. The aim of this study was to examine the ameliorating effects of S. boulardii on Citrobacter rodentium colitis in vivo and identify potential mechanisms of action. C57BL/6 mice received 2.5 x 10(8) C. rodentium by gavage on day 0, followed by S. boulardii (25 mg; 5 x 10(8) live cells) gavaged twice daily from day 2 to day 9. Animal weights were monitored until death on day 10. Colons were removed and assessed for epithelial barrier function, histology, and myeloperoxidase activity. Bacterial epithelial attachment and type III secreted proteins translocated intimin receptor Tir (the receptor for bacterial intimin) and EspB (a translocation apparatus protein) required for bacterial virulence were assayed. In infected mice, S. boulardii treatment significantly attenuated weight loss, ameliorated crypt hyperplasia (234.7 +/- 7.2 vs. 297.8 +/- 17.6 microm) and histological damage score (0.67 +/- 0.67 vs. 4.75 +/- 0.75), reduced myeloperoxidase activity (2.1 +/- 0.4 vs. 4.7 +/- 0.9 U/mg), and attenuated increased mannitol flux (17.2 +/- 5.0 vs. 31.2 +/- 8.2 nm.cm(-2).h(-1)). The ameliorating effects of S. boulardii were associated with significantly reduced numbers of mucosal adherent C. rodentium, a marked reduction in Tir protein secretion and translocation into mouse colonocytes, and a striking reduction in EspB expression and secretion. We conclude that S. boulardii maintained colonic epithelial barrier integrity and ameliorated inflammatory sequelae associated with C. rodentium infection by attenuating C. rodentium adherence to host epithelial cells through putative actions on the type III secretion system.
布拉酵母菌作为一种对预防和治疗感染性及炎症性肠病有效的益生菌,受到了越来越多的关注。本研究的目的是检测布拉酵母菌对柠檬酸杆菌性结肠炎的体内改善作用,并确定潜在的作用机制。C57BL/6小鼠在第0天经口灌胃接种2.5×10⁸ 柠檬酸杆菌,随后从第2天至第9天每天两次经口灌胃给予布拉酵母菌(25 mg;5×10⁸ 活细胞)。监测动物体重直至第10天死亡。取出结肠,评估其上皮屏障功能、组织学和髓过氧化物酶活性。检测细菌在上皮的附着情况以及细菌毒力所需的III型分泌蛋白易位内膜素受体Tir(细菌内膜素的受体)和EspB(一种易位装置蛋白)。在感染小鼠中,布拉酵母菌治疗显著减轻体重减轻,改善隐窝增生(234.7±7.2对297.8±17.6微米)和组织学损伤评分(0.67±0.67对4.75±0.75),降低髓过氧化物酶活性(2.1±0.4对4.7±0.9 U/mg),并减轻甘露醇通量增加(17.2±5.0对31.2±8.2 nm·cm⁻²·h⁻¹)。布拉酵母菌的改善作用与黏膜附着的柠檬酸杆菌数量显著减少、Tir蛋白分泌和易位至小鼠结肠细胞的显著减少以及EspB表达和分泌的显著减少有关。我们得出结论,布拉酵母菌通过对III型分泌系统的假定作用减弱柠檬酸杆菌对宿主上皮细胞的黏附,从而维持结肠上皮屏障完整性并改善与柠檬酸杆菌感染相关的炎症后遗症。